Legend Biotech (NASDAQ: LEGN) experienced a sharp rally on Tuesday, with shares climbing more than 35% to $34.48, nearing the session high of $35.33. The surge came after the company released early-stage clinical data for its experimental in vivo CAR-T therapy, LB2501, which generated a full response in a small patient cohort.
Promising Early Results in High-Dose Cohort
The ongoing Phase 1 trial is evaluating LB2501 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL). According to Legend, all six patients in the high-dose arm responded to treatment, with five achieving a complete response. As of the April 1 data cutoff, none of the patients had experienced a relapse. The median follow-up for this group stood at 2.2 months.
LB2501 is a novel in vivo CAR-T therapy, which aims to generate cancer-fighting immune cells directly inside the patient's body, bypassing the complex ex vivo manufacturing process required for traditional CAR-T treatments. This approach could potentially simplify treatment delivery and expand access to patients who are not candidates for standard CAR-T therapy.
Safety Profile and Additional Data
Legend reported that 12 patients have been treated in the trial so far, split between two dose groups. No dose-limiting toxicities, serious adverse events, deaths, or cases of immune effector cell-associated neurotoxicity syndrome (ICANS) were observed. Cytokine release syndrome (CRS) occurred in approximately two-thirds of patients, but all cases were Grade 2 or lower, indicating manageable side effects.
In a separate presentation at ASCO on Monday, Legend also shared data for LB2102, a CAR-T therapy targeting solid tumors. At higher doses, LB2102 achieved an objective response rate of 28.6% and a disease control rate of 78.6% in patients with relapsed or refractory small cell lung cancer or large-cell neuroendocrine carcinoma. Dr. Zhonglin Hao of the University of Kentucky Markey Cancer Center noted that treatment options remain limited for these patients and that the results support further investigation of CAR-T in solid tumors.
Market Context and Analyst Views
The broader biotech sector showed weakness on Tuesday, with the iShares Nasdaq Biotechnology ETF (IBB) trading down about 3% at $164.23. The rally in Legend shares was an outlier, driven by the specific LB2501 data rather than a sector-wide move.
Oppenheimer analyst Kostas Biliouris described the data as having a "potentially best-in-class profile" for in vivo CAR-T and a "best-in-disease" showing in NHL. He also suggested that the strong results could increase the likelihood of Legend being acquired. RBC Capital's Leonid Timashev reiterated an Outperform rating and a $64 price target, noting that while safety and competition remain overhangs, the firm remains positive on Legend's core business.
Carvykti Remains Key Commercial Driver
Legend's primary commercial product remains Carvykti, a CAR-T therapy for multiple myeloma co-developed and marketed with Johnson & Johnson (NYSE: JNJ). In the first quarter, Carvykti generated net trade sales of approximately $597 million, a 62% year-over-year increase. The drug is now available in 18 global markets.
The cell therapy space is becoming increasingly competitive. Bristol Myers Squibb's Abecma competes directly with Carvykti in multiple myeloma, while AstraZeneca acquired in vivo cell therapy specialist EsoBiotec last year in a deal that could reach $1 billion.
Looking Ahead
Legend is scheduled to present updated LB2501 data at a late-breaking oral session at the European Hematology Association (EHA) meeting on June 14 in Stockholm. The market has already reacted strongly to the early results, but the data remain based on a small number of patients with limited follow-up. Key risks include the durability of responses, safety in larger studies, regulatory hurdles, manufacturing scalability, and competitive pressures. Carvykti's FDA label carries major safety warnings, including CRS, neurological toxicities, prolonged cytopenia, and secondary malignancies, keeping safety a central focus as Legend advances its earlier-stage pipeline.
